Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says

MT Newswires Live06-22 23:14

Travere Therapeutics (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw "strong interest" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.

The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.

For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.

Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.

Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.

Price: 55.61, Change: +0.45, Percent Change: +0.83

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645075422?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 23:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645075422","market":"sh","top_or_hot":-1,"title":"Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw \"strong interest\" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.</p><p>The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.</p><p>For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.</p><p>Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.</p><p>Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.</p><p>Price: 55.61, Change: +0.45, Percent Change: +0.83</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-22 23:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw \"strong interest\" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.</p><p>The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.</p><p>For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.</p><p>Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.</p><p>Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.</p><p>Price: 55.61, Change: +0.45, Percent Change: +0.83</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645075422","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645075422","pubTimestamp":1782141289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Travere Therapeutics (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw \"strong interest\" as the first approved therapy for focal segmental glomerulosc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","TVTX":"Travere Therapeutics, Inc.","FFTY":"Innovator IBD 50 ETF","BK4007":"制药","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Wedbush表示，Travere Therapeutics以Filspari作为增长资产表现出有利的设置","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"TVTX":1,"FFTY":1.5},"content_text":"Travere Therapeutics (TVTX) shows a favorable setup on account of growth assets like Filspari, which is expected to draw \"strong interest\" as the first approved therapy for focal segmental glomerulosclerosis in the US, Wedbush Securities said in a note Monday.The brokerage said Filspari patient start forms reached 993 in Q1, up 9% quarter-on-quarter, and are expected to increase to about 1,200 in Q2.For Q2, Wedbush said it expects US Filspari revenue of $135 million, compared with consensus of $131 million, assuming $6 million for FSGS and $129 million for the IgA nephropathy indication.Additionally, Wedbush increased its fiscal 2027 and beyond Filspari revenue trajectory on account of both higher net pricing and uptake in the FSGS segment, according to the note.Wedbush Securities raised its price target to $61 from $55, and maintained its outperform rating on the stock.Price: 55.61, Change: +0.45, Percent Change: +0.83","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645075422","isCrawlerRequest":true}